Valneva and limmatech announce first vaccination in phase 2 infant study of tetravalent shigella vaccine candidate s4v2

Saint herblain (france) and schlieren (zurich) , april 9, 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, and limmatech biologics ag, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a phase 2 infant safety and immunogenicity study of shigella4v2 (s4v2), the world's most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis.
VALN Ratings Summary
VALN Quant Ranking